A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia

Trial Profile

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Amikacin (Primary) ; Antibacterials
  • Indications Gram-negative infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms INHALE-1
  • Sponsors Bayer
  • Most Recent Events

    • 05 May 2017 Status changed from recruiting to completed.
    • 01 Mar 2017 According to a Nektar Therapeutics media release, top-line data from the INHALE phase III programare expected in the middle of 2017.
    • 05 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Apr 2017, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top